Review of Operations continued OUTLOOK AND PLANS INOVIQ’s mission is to transform patient lives through earlier cancer detection and more effective treatments, powered by world-class exosome technologies. The Company is strongly positioned for growth with a multi-product pipeline, strategic partners validating our patented exosome technology and an experienced leadership team to execute on strategy, deliver key milestones and enhance shareholder value. We are focused on progressing our high-value exosome diagnostic and therapeutic pipeline in FY 2027. Exosome leader Leading exosome company with platform technology developing advanced cancer diagnostics and therapeutics High-value therapeutics pipeline Preclinical CAR-exosome platform with potential cost, safety & efficacy advantages over cell therapy Critical unmet need for OC screening Clinical-stage EXO-OC test addressing critical unmet for ovarian cancer screening in 243m women globally Partnering underway Active LDT partner discussions for validation and commercialisation in US Early detection saves lives Early detection of ovarian cancer with potential to improve diagnosis, treatment and outcomes Multiple value triggers Funded to deliver upcoming catalysts in 2026 FY27 Priorities 1. Complete EXO-OC™ development & validation in average-risk and high-risk groups 2. Progress EXO-OC™ toward LDT-readiness and US laboratory partnering 3. Advance CAR-exosome therapeutics toward manufacturing readiness and future clinical development 4. Maintain disciplined capital allocation on EV diagnostic and therapeutic programs 5. Deliver key milestones that support long-term shareholder value 14 INOVIQ Limited
RkJQdWJsaXNoZXIy MjE2NDg3